PARK7 and amyotrophic lateral sclerosis: Notably, one of the recently FDA-approved compounds, such as sodium phenylbutyrate (AMX0035), has demonstrated a neuroprotective effect in ALS and in both cellular and animal models of PD by up-regulating the PARK7/DJ-1 protein [125,126].